Pages that link to "Q34457273"
Jump to navigation
Jump to search
The following pages link to The Sweet Pee model for Sglt2 mutation (Q34457273):
Displaying 33 items.
- Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects (Q28072765) (← links)
- Adverse effects and safety of SGLT-2 inhibitors (Q28082331) (← links)
- Proximal nephron (Q28388052) (← links)
- Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? (Q30426407) (← links)
- Structural selectivity of human SGLT inhibitors (Q35895528) (← links)
- Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus (Q36527897) (← links)
- Glucose metabolism in the Belgrade rat, a model of iron-loading anemia (Q36923755) (← links)
- Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney (Q37253944) (← links)
- Nephron filtration rate and proximal tubular fluid reabsorption in the Akita mouse model of type I diabetes mellitus (Q37272531) (← links)
- SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. (Q37575455) (← links)
- Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. (Q37575461) (← links)
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. (Q37981884) (← links)
- Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus (Q37990891) (← links)
- Coming full circle in diabetes mellitus: from complications to initiation. (Q38072272) (← links)
- Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus (Q38085691) (← links)
- Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. (Q38330456) (← links)
- A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans (Q38537119) (← links)
- SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule? (Q38667712) (← links)
- The next generation of therapeutics for chronic kidney disease (Q38845590) (← links)
- Effect of diuretics on renal tubular transport of calcium and magnesium (Q39169297) (← links)
- SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function (Q42153763) (← links)
- Mouse models to study kidney development, function and disease (Q44117190) (← links)
- Modelling diabetic nephropathy in mice. (Q47735079) (← links)
- Urine: Waste product or biologically active tissue? (Q49719924) (← links)
- Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects (Q50027868) (← links)
- Protective Effects of Glucagon-Like Peptide-1 Analog on Renal Tubular Injury in Mice on High-Fat Diet (Q51118569) (← links)
- Improved glycemic control in mice lacking Sglt1 and Sglt2. (Q51349034) (← links)
- Report on ISN Forefronts, Melbourne, Australia, 4-7 October 2012: tubulointerstitial disease in diabetic nephropathy (Q61512493) (← links)
- Risks and Benefits of Sweet Pee (Q82920295) (← links)
- Familial renal glycosuria and modifications of glucose renal excretion (Q86441302) (← links)
- A model of calcium transport and regulation in the proximal tubule (Q88915341) (← links)
- Tubular Deficiency of Heterogeneous Nuclear Ribonucleoprotein F Elevates Systolic Blood Pressure and Induces Glycosuria in Mice (Q91045157) (← links)
- Diabetes pharmacotherapy and effects on the musculoskeletal system (Q93364919) (← links)